KINERET efficacy in NOMID patients
In a long-term study, KINERET was shown to reduce NOMID symptoms and inflammation1
KINERET was studied in a prospective, long-term, open-label study of 43 patients with NOMID, 0.7 to 46 years of age, treated for up to 60 months.
Systemic inflammatory markers were significantly reduced in all patients treated with KINERET2
- Systemic inflammatory remission was achieved in all patients; however, remission and relapse continued to occur in patients with infections or stress3
- Inflammatory remission was defined as CRP level ≤0.5 mg/dL, ESR ≤25 mm/hour, and SAA ≤10 mg/liter3
- Patients had significant reductions in inflammatory markers from baseline at 6, 12, and 36 months and results were stable from 36 to 602,3
Study design: Clinical efficacy and safety were determined by a prospective, long-term, open-label, uncontrolled study in 43 NOMID patients 0.7 to 46 years of age. Primary endpoints included change in disease-specific Diary Symptom Sum Scores (DSSS), including fever, rash, joint pain, vomiting, and headache, as well as change in the levels of inflammatory biomarkers SAA, hsCRP, and ESR. Initial KINERET dose was 1 mg/kg to 2.4 mg/kg body weight, adjusted to 0.5 mg/kg to 1 mg/kg increments. The maximum dose actually studied was 7.6 mg/kg/day. The average maintenance dose was 3 to 4 mg/kg daily. The duration of treatment with KINERET was up to 60 months.3